Therapeutic IL-1 blockade either by substitution with recombinant human IL-1Ra (anakinra) [9] or by monoclonal antibody (canakinumab)-mediated neutralization of IL-1β [10] significantly improves disease outcomes in both AOSD and sJIA. Here, IL1B is linked to adult-onset Still disease.